Date | Price Target | Rating | Analyst |
---|---|---|---|
10/3/2024 | $135.00 | Outperform | Oppenheimer |
7/30/2024 | $130.00 | Outperform | RBC Capital Mkts |
2/22/2022 | $180.00 → $130.00 | Buy | Benchmark |
2/18/2022 | $185.00 → $165.00 | Overweight | Barclays |
9/22/2021 | $174.00 → $180.00 | Overweight | Barclays |
7/30/2021 | $200.00 → $190.00 | Buy | Roth Capital |
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
Craig-Hallum analyst Matt Hewitt maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $135 to $140.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $144 price target.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it has entered into a definitive agreement to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA® (dinutuximab beta) for the treatment of high-risk neuroblastoma, for $100 million in cash. In addition, Ligand will pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively. APEIRON is a private biopharmaceutical company based in Vienna, Austria. The company co-developed QARZIBA for the treatment of high-risk neuroblastoma in patients aged 12
FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two years Conversion to full approval based on results from the PROTECT Study, where FILSPARI delivered superior long-term kidney function preservation compared to the active comparator irbesartan in the only Phase 3 head-to-head trial conducted in IgAN As an oral, non-immunosuppressive and dual acting, once-daily medicine with superior long-term results vs. irbesartan, FILSPARI has the potential to become foundational care in IgAN Ligand
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on Tuesday, September 10, 2024, at 8:30 a.m. Eastern Time. Management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their H.C. Wainwright representative. About Ligand Pharmaceuticals Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this b
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapiesCombined company is expected to have approximately $80.5 million of cash and cash equivalents at closing, including approximately $78.9 million from an oversubscribed private financing with participation from a syndicate of leading healthcare-dedicated investors, which is expected to provide cash runway into the second half of 2027Anticipated cash and cash equivalents are expected to fund combined company through multiple clinical trial milestones, including pivotal P
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information Date: Tuesday, August 6, 2024 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Conference Call: (800) 715-9871 (U.S. & Canada) (646) 307-1963 (International) Conference ID is 8755336 Webcast: Live and replay webcasts of the call are avail
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
SC 13G - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
10-Q - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
Oppenheimer initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $135.00
RBC Capital Mkts initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $130.00
Benchmark reiterated coverage of Ligand Pharmaceuticals with a rating of Buy and set a new price target of $130.00 from $180.00 previously
Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "
LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier will also be a member of 4D's Audit and Risk Committee and will serve as the Company’s “audit committee financial expert” under SEC and Nasdaq rules. “With over 25 years of extensive senior operational, international and financial management experience in the pharmaceutical and biotechnology industry, Paul will be able to provide 4D pharma with invaluable insights as we continue to execute